Abstract |
This was a nonrandomized, open-label, controlled trial in patients with colorectal ACFs. The participants were allocated to LTRA or observation groups. Patients in the LTRA group received 10 mg of montelukast orally daily for 8 weeks. After the intervention, colonoscopy was performed to evaluate the changes in the number of ACFs.
From November 2017 to March 2020, 40 patients were enrolled. The first 30 were assigned to the LTRA group, and the remaining 10 were assigned to the observation group. In the LTRA group, the mean change in the number of ACFs per patient at 8 weeks from baseline was -2.4 ± 2.2, while the mean change in the observation group was 0.4 ± 2.3 (P = 0.002). There were no severe adverse events.
This is the first study to explore the effect of LTRAs against colorectal ACF formation in humans. LTRAs are potential candidates for chemoprevention in colorectal cancer. PREVENTION RELEVANCE:
|
Authors | Takuma Higurashi, Keiichi Ashikari, Shigeki Tamura, Yusuke Saigusa, Tomohiro Takatsu, Noboru Misawa, Tsutomu Yoshihara, Tetsuya Matsuura, Akiko Fuyuki, Hidenori Ohkubo, Takaomi Kessoku, Kunihiro Hosono, Masato Yoneda, Atsushi Nakajima |
Journal | Cancer prevention research (Philadelphia, Pa.)
(Cancer Prev Res (Phila))
Vol. 15
Issue 10
Pg. 661-668
(10 04 2022)
ISSN: 1940-6215 [Electronic] United States |
PMID | 36083855
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | ©2022 American Association for Cancer Research. |
Chemical References |
|
Topics |
- Aberrant Crypt Foci
(drug therapy, prevention & control)
- Carcinogenesis
- Chemoprevention
- Colorectal Neoplasms
(drug therapy, prevention & control)
- Humans
- Leukotriene Antagonists
(therapeutic use)
- Prospective Studies
|